BridgeBio Pharma, Inc.
BBIO
$38.34
$0.320.84%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -667.97M | -535.76M | -438.86M | -453.82M | -538.26M |
| Total Depreciation and Amortization | 5.76M | 6.08M | 6.29M | 6.39M | 6.46M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 20.71M | -23.08M | -58.73M | -11.98M | 117.21M |
| Change in Net Operating Assets | 141.08M | 32.04M | 41.08M | 44.53M | -188.34M |
| Cash from Operations | -500.42M | -520.73M | -450.22M | -414.88M | -602.94M |
| Capital Expenditure | -238.00K | -933.00K | -1.32M | -1.62M | -1.99M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -140.00K | -140.00K | -140.00K | -98.00K | 0.00 |
| Other Investing Activities | 36.81M | 61.85M | 65.41M | 65.12M | 66.48M |
| Cash from Investing | 36.43M | 60.78M | 63.95M | 63.41M | 64.49M |
| Total Debt Issued | 1.08B | 950.00M | 450.00M | 450.00M | 450.00M |
| Total Debt Repaid | -459.00M | -473.42M | -473.42M | -473.42M | -473.42M |
| Issuance of Common Stock | 10.76M | 323.15M | 320.64M | 631.20M | 632.35M |
| Repurchase of Common Stock | -54.90M | -7.78M | -8.93M | -10.10M | -9.30M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -42.62M | -43.50M | -18.29M | -21.35M | -18.80M |
| Cash from Financing | 529.24M | 748.46M | 270.00M | 576.34M | 580.83M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 65.25M | 288.51M | -116.26M | 224.87M | 42.39M |